Advanced Medical Solutions Group plc · LSE:AMS
Advanced Medical Solutions — FY2020 Earnings Presentation
21 slides from Advanced Medical Solutions's earnings presentation, Mar 17, 2021
Slide 1: A world-leading company in surgical and woundcare innovation
A world-leading company in surgical and woundcare innovation Preliminary results for the year ended 31 December 2020 17 March 2021
Slide 2: Financial Highlights
Financial Highlights – Full year revenue of £86.8 million (2019: £102.4 million) and adjusted profit before tax of £13.4 million (2019: £26.6 million) reflecting COVID-19 impacts across all products and regions – Strong net cash position of £53.8 million (2019: £64.8 million) after £22.0 million Ral
Slide 3: Operational Highlights (incl. post period end)
Operational Highlights (incl. post period end) – All manufacturing sites operated throughout the COVID-19 pandemic servicing customers and meeting order demand – Group sales and profitability in line with current consensus having been heavily impacted by COVID-19 – Approval and restricted launch of
Slide 4: Product Progress: LiquiBand® Range
Product Progress: LiquiBand® Range LiquiBand® Update LiquiBand® Rapid – FDA 510(k) approval received in March 2020 – Commercial launch planned in 2021 LiquiBand® XL – Successful completion of LiquiBand® XL clinical trials in 2020 – On track for 510(k) approval and launch towards the end of 2021, all
Slide 5: Product Progress: Sealantis & Biomatlante
Product Progress: Sealantis & Biomatlante Sealantis – Positive feedback from commercial research activity completed with EU KOLs in 2020 – Post period end, patient enrolment for the first human clinical study of Seal-G® and Seal-G® MIST began – CE mark approval for Seal-G® MIST, and an extension of
Slide 6: Product Progress: Raleigh & Woundcare R&D
Product Progress: Raleigh & Woundcare R&D Raleigh – Raleigh acquisition enhances the Group’s woundcare capabilities and growth – A good fit with acquisition strategy, with positive growth prospects, as well as potential for significant cross-selling and cost saving synergies Woundcare R&D – Addressa
Slide 7: Licensing and Acquisitions Strategy
Licensing and Acquisitions Strategy – Our selection criteria remains unchanged: – Products or technologies that enable AMS to leverage its Woundcare customer base or surgical routes to market – Surgically-focused companies with product synergies, strong R&D capability and proprietary products AMS co
Slide 8: Financial Summary
Financial Summary
Slide 9: Financial Overview
Financial Overview – COVID-19 restrictions disrupted the entire market and resulted in a significant slowdown in surgical and wound treatment volumes – Despite this, the Group remained profitable and generated strong operational cash flows, whilst continuing to invest in key projects 2020 financial
Slide 10: FY 2020 Operating Margins
FY 2020 Operating Margins Margins heavily impacted by lower volumes £M Surgical Business Unit – Much lower volumes caused by COVID-19 restrictions 28.4% 80.0 30.0% resulted in under-absorption of fixed costs and 25.0% 60.0 18.1% reduced gross and net margins 20.0% 40.0 15.0% – Fixed costs relating t
Slide 11: FY 2020 Results: Surgical
FY 2020 Results: Surgical Surgical Revenue 60000 Revenue down 11% to £50.2 million (2019: £56.5 million) Advanced Closure – LiquiBand® 50000 - Revenue down 24% to £22.8 million (2019: £30.1 million) Internal Fixation and Sealants 40000 - LiquiBandFix8®revenue down 20% to £2.1 million (2019: £2.6 mil
Slide 12: FY 2020 Results: Woundcare
FY 2020 Results: Woundcare Revenue down 20% to £36.6 million (2019: £45.8 million) Woundcare Revenue Infection Control 50000 - Revenue down 25% to £15.3 million (2019: £20.6 million) 45000 - To support our partners we did not enforce annual 40000 minimum volumes in a number of cases 35000 - Commerci
Slide 13: Revenue by Product
80.0 70.0 60.0 50.0 30.0 20.0 10.0 00 Revenue by Product Infection control Woundcare Exudate management Surgical RESORBA a ~~ Traditional closure FY 20 YoY GROWTH % (constant currency) -30.0% 20.0% 10.0% 13
Slide 14: Cash Flow Summary
Cash Flow Summary 2020 2019 £ million £ million Profit from operations 10.7 24.2 Depreciation and Amortisation 6.8 5.8 Working capital movements 4.9 (5.2) Share-based payments expense 1.6 1.9 Taxation (3.7) (5.9) Net cash inflow from operating activities 20.4 20.8 Capital expenditure and capitalised
Slide 15: Foreign Exchange Hedging
Foreign Exchange Hedging Currency Cash Flows - GBP 000 equivalent 60,000 GBP 50,000 USD GBP 40,000 EUR EUR USD GBP 30,000 GBP 20,000 USD 10,000 USD EUR USD EUR 0 GBP EUR (10,000) (20,000) (30,000) Sales Costs, capital spend Net cash flow Contracts in place for Cash flow after fx + dividends (pre fx
Slide 16: Summary and Outlook
Summary and Outlook
Slide 17: Our Strategy for Growth
Our Strategy for Growth Product Operational Commercial Leverage – Quality Innovation excellence Flexibility acquisitions outcomes • Developing or • Quality of • Continue global • Acquire for patients acquiring high manufacturing expansion complementary quality products and security of through direct
Slide 18: Multiple Product Growth Drivers
Multiple Product Growth Drivers Collagens LiquiBandFix8® Strong portfolio of high – Sutures Internal sealants margin surgical and advanced woundcare devices Track record of commercial – LiquiBand® Bone success substitutes Potential for further market – share growth in all key categories Fibres Activ
Slide 19: 2021 Expected Newsflow
2021 Expected Newsflow – US LiquiBand®: – Approval and launch of LiquiBand® XL – Completion of US LiquiBandFix8® PMA study – CE mark for Seal-G® MIST and extended approval for Seal-G® open device expected imminently – Full anti-microbial claim for Silver High Performance Dressing expected by the end
Slide 20: Summary and Outlook
Summary and Outlook – Despite ongoing COVID-19 related challenges, the Group has seen a continuing gradual recovery across the business – 2021 has started well with a healthy order book in both Business Units Building organic and – Group set for strong organic growth acquisitive growth; underpinned
Slide 21: Contact Us
Contact Us Advanced Medical Solutions Group plc Premier Park, 33, Road One Winsford Industrial Estate Winsford, Cheshire CW7 3RT, UK Chris Meredith Chief Executive Officer Eddie Johnson Chief Financial Officer corporate@admedsol.com +44 (0)1606 863 500 www.admedsol.com
Advanced Medical Solutions Group — FY2020 Earnings Presentation on 6ix